[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Weill Cornell Medical College in Qatar\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":119},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,66,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644973","qatar-cardiometabolic-cohort-100644973",false,"NCT07675928","Qatar Cardiometabolic Cohort","Qatar Cardiometabolic Cohort (QCMC)","Inclusion Criteria:\n\n* Qataris\n* Long-term residents (≥15 years of residence in Doha) who are not planning to leave Qatar voluntarily within the next 5 years.\n* Age ≥18 years.\n* English or Arabic speaker.\n* Presence of either atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.\n\n  1. ASCVD:\n\n     ASCVD is defined as either clinical ASCVD or unequivocally documented ASCVD on imaging, based on the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease in patients with diabetes.\n\n     i.Clinical ASCVD: History or presence of any of the following atherosclerotic events or revascularization in major arterial territories:\n     1. Coronary Artery Disease (CAD)\n\n        * Myocardial infarction (ST-elevation myocardial infarction (STEMI) or Non-ST-elevation myocardial infarction (NSTEMI))\n        * Stable or unstable angina with angiographic stenosis ≥50%\n        * History of coronary revascularization (Percutaneous coronary intervention (PCI) or Coronary artery bypass graft surgery (CABG))\n     2. Cerebrovascular Disease\n\n        * Ischemic stroke or transient ischemic attack (TIA)\n        * Symptomatic carotid artery stenosis ≥50% or prior carotid intervention\n     3. Peripheral Arterial Disease (PAD)\n\n        * Intermittent claudication with objective evidence of arterial obstruction\n        * Prior peripheral revascularization, limb amputation due to ischemia, or Ankle-brachial index ABI \\\u003C0.9\n     4. Aortic Atherosclerotic Disease •Aortic aneurysm (abdominal or thoracic) of atherosclerotic origin ii.Unequivocally Documented ASCVD on Imaging:\n\n     \u003C!-- -->\n\n     1. Coronary artery calcium (CAC) score \\>100 Agatston units or \\>75th percentile for age and sex\n     2. Coronary CT angiography or invasive angiography showing ≥50% stenosis in ≥1 major epicardial artery\n     3. Carotid ultrasound or angiography showing plaque or ≥50% stenosis\n     4. Lower-limb CT\u002FMR\u002FDoppler angiography showing atherosclerotic plaque or stenosis ≥50%\n  2. Very High Cardiovascular Risk i. In non-diabetic patients (ESC 2021 CVD Prevention Guidelines):\n\n     * 10-year fatal\u002Fnon-fatal ASCVD risk ≥10% using SCORE2 (ages 40-69), or ≥15% using SCORE2-OP (≥70 years)\n     * Severe chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² ii.In diabetic patients (ESC 2023 Diabetes \\& CVD Guidelines):\n     * 10-year cardiovascular risk ≥20% using SCORE2-Diabetes\n     * Severe target organ damage:\n\n  \u003C!-- -->\n\n  1. eGFR \\\u003C45 mL\u002Fmin\u002F1.73m² (regardless of albuminuria)\n  2. eGFR 45-59 mL\u002Fmin\u002F1.73m² with microalbuminuria (UACR 30-300 mg\u002Fg) or proteinuria (UACR \\>300 mg\u002Fg)\n  3. Microvascular disease in at least three sites (e.g., microalbuminuria, retinopathy, neuropathy)\n\nExclusion Criteria:\n\n* Type 1 diabetes or monogenic diabetes (e.g., MODY).\n* Pregnancy (self-reported).\n* Active cancer, under medical or radiation therapy or terminal, or cancer in remission \\\u003C 1 year.\n* Chronic immune or chronic infectious diseases.\n* End stage renal disease (ESRD) (estimated glomerular filtration rate \\\u003C15 mL\u002Fmin\u002F1.73m²).\n* Prisoners.\n* Inability or unwillingness to provide informed consent, including language barriers.\n* Mental incapacity.","ALL","18 Years",{"count":19,"type":20},3000,"ESTIMATED","5 Years","OBSERVATIONAL","Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic cardiovascular disease events.",[25],"Cardiometabolic Diseases",[27,28,29],"cardiometabolic diseases","atherosclerotic cardiovascular disease","diabetes","NOT_YET_RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":20},"2026-06-01",{"date":38,"type":20},"2036-06-30",{"name":40,"class":41},"Weill Cornell Medical College in Qatar","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100635731","role-of-endothelial-progenitor-cells-dysregulation-and-inflammation-in-the-pathophysiology-of-cardiovascular-complications-of-type-2-diabetes-100635731","NCT07556497","Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes","Inclusion Criteria:\n\n* T2D\n* Males and females\n* Older than 18 years of age\n* Willingness to participate in the study and provide written consent form\n* Consent to having peripheral blood withdrawals and urine collection for the study requirement.\n\nExclusion Criteria:\n\n* Unable to meet the inclusion criteria\n* Type I diabetes, MODY diabetes or other form of diabetes\n* Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to).\n* Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis).\n* Evidence of malignancy within the past 5 years",true,{"count":51,"type":20},90,"6 Months","This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.",[55,56],"Diabete Type 2","Cardio Vascular Disease","RECRUITING","2026-04-21",{"date":60,"type":34},"2026-04-29",{"date":62,"type":34},"2020-11-17",{"date":64,"type":20},"2026-12-31",{"name":40,"class":41},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":75,"studyType":22,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":42},"100632601","qatar-cardiometabolic-retrospective-cohort-analysis-using-artificial-intelligence-100632601","NCT07515807","Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence","QCRC-AI","Inclusion Criteria:\n\n* Age ≥ 18\n* Qatari and Arab participants\n* Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)\n* Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%\n\nExclusion Criteria:\n\n* Non-Qatari or non-Arab participants\n* Non-diabetic: HbA1C \\\u003C 5.7%\n* This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.",{"count":74,"type":20},10000,"2 Years","Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.",[56,78,79,80,81],"Acute Coronary Syndromes (ACS)","Type 2 Diabetes","Pre Diabetes","Artifical Intelligence","2026-04-15",{"date":58,"type":34},{"date":85,"type":20},"2026-07-16",{"date":87,"type":20},"2030-07-16",{"name":40,"class":41},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":42},"100508709","air-pollution-and-cardiovascular-disease-in-qatar-an-interventional-study-to-reduce-blood-pressure-100508709","NCT05903950","Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure","Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure: the APCIQ-BP Trial","APCIQ-BP","Inclusion Criteria:\n\n* Non-smokers (100% abstinence from use of any smoking or vaping product during the prior year)\n* Age ≥18 and less than 60 years old\n* Living in a single residence (home, apartment) located anywhere in Qatar\n* Mild systolic hypertension: screening visit systolic BP 130 to 159 mm Hg (off treatment or taking ≤ 2 BP medications that have been stable without changes during prior 4 weeks) plus ≥ 2 more additional criteria for the metabolic syndrome:\n\n  * Waist circumference ≥102 cm if male and ≥88 cm if female\n  * Fasting triglycerides ≥150 mg\u002FdL (or taking a triglyceride-lowering medication)\n  * HDL-C ≤ 40 mg\u002FdL if male and ≤ 50 mg\u002FdL if female (or taking an HDL-raising medication),\n  * Fasting glucose ≥100 mg\u002FdL\n\nExclusion Criteria:\n\n* Pregnancy (self-reported)\n* Screening visit urine positive for cotinine (NicAlert \\>100 ng\u002FmL)\n* Living with an active smoker who smokes indoors (by self-report)\n* High risk conditions that prohibit allowing home BP to be \\>130\u002F80 mm Hg during the10-week trial including any cardiovascular disease (coronary artery disease, prior stroke, heart failure, peripheral arterial disease, aneurysm) or ≥ stage 3 kidney disease (estimated glomerular filtration rate \\\u003C 60 ml\u002Fmin)\n* A medical condition placing the participant at risk from participation (per investigators)\n* Expected overnight travel outside their residence during the study\n* HEPA filter within the air conditioners of the residence (self-reported) or individual use of HEPA filter\n* Unable to comprehend\u002Fsign an informed consent\n* Lung disease requiring oxygen\n* Cancer receiving treatment\n* Screening visit: BP ≥160\u002F100 mm Hg or fasting blood glucose ≥126 mg\u002FdL and confirmed diabetes with follow-up HbA1c ≥6.5%. If glucose is elevated ≥126 mg\u002FdL but HbA1c\\\u003C6.5%, they could still participate.\n* Medication changes in past 4 weeks. If participants are on medications for high BP or hyperlipidemia, they will need to have had stable therapy during prior 10 weeks with no planned changes during the study\n* Left upper arm circumference \\>17 inches as this will make BP levels inaccurate with the home monitor used\n* Acute illness or infectious symptoms within the prior 4 weeks.","60 Years",{"count":99,"type":20},100,"INTERVENTIONAL",[102],"NA","The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.",[105,106],"Hypertension, Systolic","Metabolic Syndrome",[108,109,110],"hypertension","metabolic syndrome","air pollution","2025-07-16",{"date":113,"type":34},"2025-07-20",{"date":115,"type":34},"2024-11-03",{"date":117,"type":20},"2026-04",{"name":40,"class":41},""]